Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + nab-paclitaxel as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma
ChiCTR2200056550Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200056550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056550.